Clopidogrel bisulfate modulates metabolic activity and ERK-associated signaling in human endothelial progenitor cells under oxidative stress: an in vitro study Authors: Seoho Jahng, Mijung Lee, Manho Kim Published: 2026 ABSTRACT AbstractEndothelial progenitor cells (EPCs) play a critical role in vascular repair and neovascularization by contributing to endothelial regeneration. While clopidogrel bisulfate is widely used as an antiplatelet agent, its direct cellular effects on EPC biology remain largely unexplored. This study aimed to determine whether clopidogrel bisulfate modulates human EPC proliferation, survival, and intracellular signaling in vitro. Human EPCs were isolated from peripheral blood mononuclear cells and characterized by Dil-ac-LDL uptake and CD34 immunostaining. Cells were treated with clopidogrel bisulfate (0, 5, or 10 µM) for 48 h. Proliferation, apoptosis, and cell viability were assessed using microscopy, Annexin V/PI flow cytometry, and CCK-8 assays. Western blotting was used to evaluate apoptosis-related proteins (Bax, Bcl-2) and signaling pathways (p-ERK). Clopidogrel bisulfate-treated EPCs maintained characteristic morphology and exhibited an apparent increase in cell density compared with untreated controls, without significant induction of apoptosis. CCK-8 assay revealed increased absorbance at later reaction time points, indicating enhanced cellular metabolic activity. In addition, under basal conditions, no consistent changes in the Bax/Bcl-2 ratio or ERK phosphorylation were observed. In contrast, under H2O2-induced oxidative stress conditions, clopidogrel bisulfate reduced the Bax/Bcl-2 ratio and increased ERK phosphorylation, suggesting context-dependent modulation of intracellular signaling pathways. These findings suggest that clopidogrel bisulfate influences EPC behavior by modulating metabolic activity and intracellular signaling, particularly under oxidative stress conditions. Beyond its antiplatelet effects, clopidogrel bisulfate may support endothelial repair through EPC-mediated mechanisms as a therapeutic agent in vascular disease.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-51953-6.Keywords: Endothelial progenitor cells, Clopidogrel bisulfate, ERK signaling, Vascular repair, EPC proliferationSubject terms: Cancer, Cell biology Introduction Endothelial progenitor cells (EPCs), first identified in adult peripheral blood, play an essential role in postnatal vasculogenesis and vascular repair by differentiating into mature endothelial cells and secreting pro-angiogenic cytokines1,2. These cells, primarily derived from bone marrow, contribute significantly to endothelial regeneration and vascular homeostasis, and their dysfunction has been implicated in the pathogenesis of various vascular and metabolic disorders, including atherosclerosis, diabetes, and stroke3. Consequently, EPCs have gained attention as both biomarkers and potential therapeutic targets for cardiovascular and ischemic diseases. Clopidogrel bisulfate, a P2Y12 receptor antagonist, is widely prescribed for the prevention of thrombotic vascular events due to its potent antiplatelet activity4. While its clinical efficacy in platelet inhibition is well established, accumulating evidence suggests that clopidogrel bisulfate might exert pleiotropic effects beyond hemostasis. These include modulation of endothelial function, attenuation of vascular inflammation, and improvement of arterial compliance, all of which might influence vascular repair processes5,6. However, despite these vascular-protective actions, the direct impact of clopidogrel bisulfate on EPC biology remains poorly characterized. Given the pivotal role of EPCs in maintaining vascular integrity, elucidating whether clopidogrel bisulfate can influence EPC behavior represents a critical step toward understanding its broader regenerative potential in the vasculature. To the best of our knowledge, no studies have comprehensively investigated how clopidogrel bisulfate modulates EPC-specific cellular mechanisms such as proliferation, survival, and intracellular signaling. Pharmacological modulation of EPC function might provide a novel strategy for treating diseases associated with impaired vascular integrity. Here, we investigated the cellular and molecular effects of clopidogrel bisulfate on human EPCs derived from peripheral blood. EPCs were characterized by canonical markers, including Dil-ac-LDL uptake and CD34 immunofluorescence, confirming the validity of our endothelial in vitro model7. Upon clopidogrel bisulfate exposure, EPCs retained their characteristic morphology and exhibited an apparent increase in cell density without a significant change in apoptosis. Clopidogrel bisulfate treatment was associated with increased cellular metabolic activity and context-dependent changes in intracellular signaling pathways, including modulation of the Bax/Bcl-2 ratio and ERK phosphorylation under oxidative stress conditions. These findings suggest that clopidogrel bisulfate may influence EPC-related cellular responses beyond its established antiplatelet effects. Results Isolation and characterization of human EPCs To confirm the successful isolation and expansion of functional human EPCs suitable for subsequent vascular biology and regenerative medicine experiments, EPCs were isolated from peripheral blood mononuclear cells (PBMCs) using density-gradient centrifugation with Histopaque-1077. Following isolation, PBMCs were seeded onto gelatin-coated culture plates and maintained in endothelial growth medium-2 (EGM-2). Adherent colonies exhibiting characteristic endothelial morphology emerged, indicating successful EPC culture (Fig. 1A). Isolation, culture, and characterization of human EPCs. (A) Representative phase-contrast images showing morphology of EPCs derived from PBMCs. (B) Fluorescence images confirming EPC phenotype. Left: Dil-ac-LDL uptake assay demonstrates active endocytic function typical of endothelial cells (green); nuclei were counterstained with DAPI (blue). Right: Immunofluorescence staining for CD34 shows positive expression mainly at the cell membrane and partially in the cytoplasm (green), with DAPI nuclear staining (blue). (C) Flow cytometry analysis of EPC surface markers. Cells were positive for CD31 (91.3%), CD34 (88.1%), CD105 (88.7%), and KDR (61.6%), and negative for CD133 (0.5%), consistent with an ECFC-like phenotype. Phenotypic characterization of the cultured cells was performed to confirm EPC identity. Active endocytosis, characteristic of endothelial lineage cells, was confirmed by Dil-ac-LDL uptake assay. In addition, immunofluorescence staining revealed robust expression of CD34, a well-established marker of hematopoietic and EPCs. CD34 signal was predominantly localized to the cell membrane with partial cytoplasmic distribution, consistent with its known expression pattern (Fig. 1B). To further characterize the cell population, flow cytometry analysis was performed. The cells were positive for CD31 (91.3%), CD34 (88.1%), CD105 (88.7%), and KDR (61.6%), and negative for CD133 (0.5%). This marker profile is consistent with an endothelial colony-forming cell (ECFC)-like phenotype (Fig. 1C). Determination of Clopidogrel Bisulfate Concentration and Its Effect on EPC Morphology and Cell Number To evaluate the effect of clopidogrel bisulfate on the number and morphology of EPCs, cells were treated with 0 µM (control), 5 µM, and 10 µM concentrations for 48 h. Phase-contrast microscopy revealed that EPCs maintained their characteristic rounded and compact morphology across all treatment groups, with no overt signs of cytotoxicity or morphological disruption (Fig. 2). An apparent increase in cell density was observed in response to clopidogrel bisulfate treatment in both the 5 µM and 10 µM groups compared to the untreated control. (Fig. S1) Effects of clopidogrel bisulfate on EPC morphology and cell density after 48 h of treatment. Representative phase-contrast images of EPCs treated with 0 µM (Control), 5 µM (CB_5 µM), and 10 µM (CB_10 µM) clopidogrel bisulfate for 48 h are shown. EPCs in all groups maintained a typical rounded and compact morphology consistent with endothelial progenitor cell characteristics. An apparent increase in cell density was observed in clopidogrel bisulfate-treated groups compared with the control. Images were captured at 10× magnification. Quantitative analysis of EPC density is presented in Fig. S1. Effects of clopidogrel bisulfate on apoptosis and cell viability in EPCs To investigate whether clopidogrel bisulfate influences apoptosis in human EPCs, Annexin V-FITC/propidium iodide (PI) staining followed by flow cytometry was performed after 48 h of treatment with 5 µM and 10 µM clopidogrel bisulfate. The proportion of apoptotic cells, including both early (Annexin V⁺/PI⁻) and late (Annexin V⁺/PI⁺) apoptotic populations, did not significantly differ between clopidogrel bisulfate-treated and control groups (Fig. 3A, B). Assessment of apoptosis and viability in EPCs following clopidogrel bisulfate treatment. (A) Flow cytometry dot plots showing Annexin V-FITC/PI staining of EPCs after 48-hour treatment with clopidogrel bisulfate (5 µM and 10 µM). Controls include untreated cells and single-stained controls. Q1: necrotic cells (Annexin V⁻/PI⁺), Q2: late apoptotic (Annexin V⁺/PI⁺), Q3: viable cells (Annexin V⁻/PI⁻), Q4: early apoptotic (Annexin V⁺/PI⁻). (B) Quantification of apoptotic cells (early + late apoptosis) across groups. No significant increase in apoptosis was observed in clopidogrel bisulfate -treated cells compared to controls. (C) CCK-8 assay showing EPC metabolic activity after 48-hour treatment with clopidogrel bisulfate. Absorbance was measured at different reaction times (0, 0.5, and 2 h) after addition of the CCK-8 reagent. Clopidogrel bisulfate-treated EPCs exhibited significantly increased CCK-8 absorbance at 0.5 h and 2 h compared to the untreated control, with a greater increase observed at 2 h. (D) EdU incorporation assay showing proliferative activity of EPCs after 48-hour treatment with clopidogrel bisulfate (5 µM and 10 µM). Representative fluorescence images of EdU-positive cells (green) and nuclei stained with Hoechst (blue) are shown. Quantification was performed by calculating the ratio of EdU-positive cells to total nuclei (EdU/Hoechst), and values were normalized to the untreated control. Clopidogrel bisulfate-treated groups exhibited a significant increase in proliferative activity compared to the control. Data are presented as mean ± SD (n = 3). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s post-hoc test. ***p < 0.001 vs. untreated control. CCK-8 assay demonstrated a significant increase in metabolic activity, as reflected by increased absorbance, in clopidogrel bisulfate-treated EPCs compared to untreated controls at 0.5 h and 2 h after reagent addition, with a greater increase observed at 2 h (Fig. 3C). No difference was observed at 0 h. To further assess proliferative activity, an EdU incorporation assay was performed. Clopidogrel bisulfate treatment (5 and 10 µM) increased the proportion of EdU-positive cells compared to the untreated control (Fig. 3D), supporting a potential effect on proliferative activity. Impact of clopidogrel bisulfate on cell signaling pathways and apoptosis mechanisms in EPCs To investigate the effects of clopidogrel bisulfate on apoptosis-related and ERK signaling pathways, Western blot analysis was performed under both basal and oxidative stress conditions. Under basal conditions, clopidogrel bisulfate treatment did not induce significant changes in the Bax/Bcl-2 ratio or ERK phosphorylation (Fig. 4A). Effects of clopidogrel bisulfate on apoptosis- and survival-related signaling pathways in EPCs. (A) Effects of clopidogrel bisulfate on the Bax/Bcl-2 ratio and ERK phosphorylation under basal conditions. EPCs were treated with clopidogrel bisulfate (5 µM and 10 µM) for 48 h. Western blot analysis was performed to assess the expression of Bax, Bcl-2, phosphorylated ERK (p-ERK), and total ERK. Clopidogrel bisulfate treatment did not induce significant changes in the Bax/Bcl-2 ratio or ERK phosphorylation under basal conditions. (B) Effects of clopidogrel bisulfate on the Bax/Bcl-2 ratio and ERK phosphorylation under H2O2-induced oxidative stress conditions and ERK inhibition. EPCs were treated with clopidogrel bisulfate (10 µM) in the presence or absence of H2O2 and the ERK inhibitor U0126. Experimental groups included Control, CB (10 µM clopidogrel bisulfate), and CB_U0126 (10 µM clopidogrel bisulfate + U0126) under basal conditions, as well as Control (H2O2), CB (10 µM clopidogrel bisulfate + H2O2), and CB_U0126 (10 µM clopidogrel bisulfate + U0126 + H2O2) under oxidative stress conditions. Western blot analysis was performed to assess Bax, Bcl-2, p-ERK, and total ERK levels. Under oxidative stress conditions, clopidogrel bisulfate significantly reduced the Bax/Bcl-2 ratio and increased the p-ERK/ERK ratio, whereas these effects were attenuated in the presence of U0126. Densitometric quantification is presented as relative Bax/Bcl-2 and p-ERK/ERK ratios normalized to the respective control. β-actin was used as a loading control. Data are expressed as mean ± SD (n = 2 for Bax/Bcl-2 analysis in Fig. 4A; n = 3 for other analyses). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s post-hoc test. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. respective control. Original blot images are in Fig. S2 and Fig. S3. To further evaluate these effects, additional experiments were performed under H₂O₂-induced oxidative stress conditions. Under these conditions, clopidogrel bisulfate (10 µM) significantly reduced the Bax/Bcl-2 ratio compared to the H2O2-treated control (Fig. 4B), indicating a shift in apoptotic balance. This effect was not statistically significant in the presence of the ERK inhibitor U0126. In parallel, clopidogrel bisulfate significantly increased the p-ERK/ERK ratio under oxidative stress conditions, whereas this increase was markedly attenuated by co-treatment with U0126 (Fig. 4B). Discussion In this study, we investigated the direct cellular effects of clopidogrel bisulfate on human EPCs under controlled in vitro conditions. Using a peripheral blood-derived ECFC-like model, we demonstrated that clopidogrel bisulfate treatment preserved cell morphology and resulted in an apparent increase in cell density after 48 h, without compromising cell viability. This finding suggests that clopidogrel bisulfate may exert cytoprotective effects and may potentially influence the growth of vascular progenitor cells. EPCs play a critical role in postnatal vascular repair and endothelial homeostasis by either differentiating into endothelial cells or exerting paracrine angiogenic effects1,2. The maintenance of their functional activity is an important determinant of their therapeutic potential. In the present study, CCK-8 assay revealed a significant increase in signal intensity at later reaction time points following clopidogrel bisulfate treatment, indicating enhanced cellular metabolic activity. However, when considered independently, CCK-8 measurements primarily reflect dehydrogenase activity and should be interpreted as an indicator of metabolic activity rather than a direct measure of cell survival or proliferation. Consistent with this interpretation, apoptosis analysis demonstrated that clopidogrel bisulfate did not significantly alter the proportion of apoptotic cells, suggesting that the observed increase in CCK-8 signal is unlikely to be driven by a reduction in cell death alone. Instead, these findings support the possibility that clopidogrel bisulfate modulates EPC metabolic activity under the tested conditions. In addition, EdU incorporation analysis showed an increased proportion of EdU-positive cells following clopidogrel bisulfate treatment, suggesting a potential effect on proliferative activity. However, these findings should be interpreted with caution, as the overall evidence does not establish a definitive increase in proliferation. Further mechanistic insight was provided by the analysis of apoptosis-related proteins and intracellular signaling pathways. Under basal conditions, clopidogrel bisulfate did not induce significant changes in the Bax/Bcl-2 ratio. In contrast, under H2O2-induced oxidative stress conditions, clopidogrel bisulfate significantly reduced the Bax/Bcl-2 ratio, suggesting modulation of apoptotic balance8,9. In parallel, ERK phosphorylation was not consistently altered under basal conditions but was significantly increased under oxidative stress. This increase was attenuated by ERK inhibition, indicating that ERK-associated signaling may be involved in the regulation of apoptotic balance under oxidative stress conditions. Although these findings suggest a potential link between ERK signaling and apoptotic regulation, a direct mechanistic relationship cannot be established from the current data and requires further investigation10,11. Notably, the potential effect on proliferative activity observed in the EdU assay was not evaluated in the context of ERK inhibition; therefore, no mechanistic link between ERK signaling and proliferative activity can be established in this study. Our findings suggest that clopidogrel bisulfate modulates EPC behavior in a context-dependent manner, particularly under oxidative stress conditions, by influencing metabolic activity and intracellular signaling pathways. These results broaden our understanding of the potential pleiotropic actions of clopidogrel bisulfate and support further exploration of its role in endothelial repair mechanisms. A limitation of this study is that clopidogrel bisulfate is a prodrug that requires hepatic metabolism to generate its active metabolite. As EPCs may have limited capacity to perform this metabolic conversion in vitro, the observed effects may not fully reflect in vivo pharmacokinetic conditions. In addition, the concentrations used in this study (5–10 µM) were selected to elicit measurable cellular responses and are within the range commonly used in previous in vitro studies (e.g., 10–20 µM)12, but may not directly correspond to physiological plasma levels of the active metabolite. Therefore, the translational relevance of these findings should be interpreted with caution. In addition, functional assays relevant to EPC biology, such as tube formation or migration assays, were not performed in this study. Further studies incorporating these assays would be valuable to better define the functional and translational relevance of the observed effects. Another limitation of this study is that experiments were performed using EPCs derived from a single donor, and replicates represent technical rather than biological variation. Although this approach was adopted to ensure phenotypic consistency, it may limit the generalizability of the findings. Conclusions In summary, our in vitro study demonstrates that clopidogrel bisulfate modulates the phenotype and functional characteristics of human EPCs. Clopidogrel bisulfate treatment was associated with increased cellular metabolic activity and context-dependent changes in intracellular signaling pathways, particularly under oxidative stress conditions. These findings suggest that clopidogrel bisulfate may exert beneficial vascular effects beyond its established antiplatelet properties, potentially supporting endothelial function and promoting regenerative capacity at the cellular level. While preliminary evidence from previous clinical reports has indicated increased circulating EPC levels with clopidogrel bisulfate treatment, further mechanistic and translational studies are needed to delineate the molecular pathways involved and to determine the therapeutic relevance of these effects in the context of vascular disease. Materials and methods Study design and rationale Previous studies have suggested that clopidogrel bisulfate and related antiplatelet agents may modulate vascular function, including effects on microparticle generation and diabetic vascular injury. However, these studies were primarily observational and lacked direct mechanistic investigation at the endothelial cell or EPC level. To address this gap, the present study aimed to evaluate the direct effects of clopidogrel bisulfate on EPC biology using a combined in vitro and clinical approach. Human EPCs were isolated from healthy donors without a history of antiplatelet medication use. In vitro experiments were conducted to assess dose- and time-dependent effects of clopidogrel bisulfate on EPC proliferation, survival, and endothelial differentiation. Isolation and culture of human EPCs and subtype characterization Peripheral blood mononuclear cells (PBMCs) were isolated from 6 mL of whole blood collected from healthy donors with no history of antiplatelet medication. PBMC isolation was performed by density-gradient centrifugation using Histopaque-1077 (Sigma–Aldrich, UK). Briefly, blood samples were carefully layered over an equal volume of Histopaque and centrifuged at 400 × g for 30 min at room temperature. The mononuclear cell layer was collected and washed twice with Hank’s Balanced Salt Solution (HBSS; Invitrogen, UK) by centrifugation at 250 × g for 10 min. Isolated PBMCs were seeded onto fibronectin-coated culture plates and cultured in endothelial growth medium-2 (EGM-2; Lonza, USA), supplemented with 5% fetal bovine serum (FBS), 1% penicillin-streptomycin, and growth factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (b-FGF), insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), ascorbic acid, and GA-1000. Culture medium was refreshed every 7 days during cell expansion. Resulting colonies were expanded and used for subsequent assays. EPCs between passages 8 and 10 were designated as “young EPCs,” while those between passages 16 and 20 were classified as “senescent EPCs.” EPC subtypes were characterized based on colony morphology and culture duration: early EPCs emerged between days 7 and 10 post-seeding and exhibited moderate proliferative capacity and expression of endothelial markers; late EPCs, also known as endothelial colony-forming cells (ECFCs), appeared between 2 and 3 weeks, displaying cobblestone morphology, higher proliferative potential, and robust expression of endothelial lineage markers. EPCs were initially obtained from multiple independent donors (approximately n ≈ 30). For subsequent in vitro experiments, cells derived from a single donor exhibiting a well-defined ECFC phenotype were used to ensure experimental consistency. All experiments were performed using technical replicates from this single donor-derived EPC population. To further characterize the cell population, flow cytometry analysis was performed using antibodies against CD31, CD34, CD105, KDR, and CD133. Data were acquired using a FACScan cytometer (BD Biosciences) and analyzed with FlowJo software. The cells exhibited high expression of CD31, CD34, CD105, and KDR, and minimal expression of CD133, consistent with an ECFC-like phenotype. Clopidogrel bisulfate treatment EPCs were treated with clopidogrel bisulfate (Samjin Pharmaceutical, South Korea) at concentrations of 0 µM (control), 5 µM, and 10 µM for up to 48 h. The culture medium was refreshed every 48 h. Doses were selected based on preliminary experiments and prior literature. Cytotoxicity and viability assays Cytotoxicity was assessed using a WST-1 assay (Roche, Germany) according to the manufacturer’s instructions. EPCs were seeded in 96-well plates and treated with clopidogrel bisulfate. At designated time points (30 min, 1 h, 2 h, and 4 h), 10 µL of WST-1 reagent was added to each well containing 100 µL of culture medium. Plates were incubated at 37 °C in 5% CO₂, and absorbance was measured at 450 nm with a reference wavelength of 650 nm using a microplate reader. Cell proliferation was evaluated using the Cell Counting Kit-8 (CCK-8; Dojindo Laboratories). Following clopidogrel bisulfate treatment, 10 µL of CCK-8 reagent was added to each well and incubated for 30 min to 4 h before measuring absorbance at 450 nm. EdU incorporation assay Proliferative activity was assessed using a 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay. EPC-like cells were treated with clopidogrel bisulfate (0, 5, and 10 µM) for 48 h and subsequently incubated with EdU according to the manufacturer’s protocol. Cells were fixed, permeabilized, and stained using a fluorescent azide reaction. Nuclei were counterstained with Hoechst dye. Fluorescence images were acquired using an inverted fluorescence microscope. The proportion of EdU-positive cells was quantified relative to total nuclei, and values were normalized to the untreated control. Immunocytochemistry EPCs (5,000 cells/well) were seeded onto glass coverslips in 24-well plates and treated with clopidogrel bisulfate as described. Cells were fixed with 4% paraformaldehyde for 15 min and permeabilized with 0.1% Triton X-100 for 5 min. After blocking with 10% normal goat serum containing 0.3 M glycine for 1 h, cells were incubated overnight at 4 °C with primary antibodies against UEA-1 lectin, VE-cadherin, CD31, CD34, KDR, and Dil-ac-LDL (all at 1:200 dilution). Alexa Fluor® 594-conjugated secondary antibodies (Invitrogen, RRID: AB_2534079) were applied for detection, and nuclei were counterstained with DAPI (1 µg/mL). Fluorescence images were captured using an inverted fluorescence microscope (BX61, Olympus, Japan). In addition, EPC density was estimated by counting the number of cells in representative phase-contrast images using ImageJ software (NIH, USA) for descriptive comparison between groups. Apoptosis analysis by flow cytometry EPCs were treated with clopidogrel bisulfate at concentrations of 5 µM and 10 µM for 48 h. Apoptosis was assessed using Annexin V-FITC and propidium iodide (PI) double staining according to the manufacturer’s protocol (Annexin V Apoptosis Detection Kit, BD Biosciences, RRID: AB_2869083). Briefly, after treatment, EPCs were harvested, washed with cold PBS, and resuspended in binding buffer. Cells were then incubated with Annexin V-FITC and PI for 15 min at room temperature in the dark. Flow cytometry was performed using a FACScan cytometer (BD Biosciences), and data were analyzed to quantify viable (Annexin V⁻/PI⁻), early apoptotic (Annexin V⁺/PI⁻), late apoptotic (Annexin V⁺/PI⁺), and necrotic (Annexin V⁻/PI⁺) populations. Western blot analysis of apoptosis- and survival-related proteins To investigate the effects of clopidogrel bisulfate on key signaling pathways, EPCs treated with 5 µM and 10 µM clopidogrel bisulfate for 48 h were lysed in RIPA buffer supplemented with protease and phosphatase inhibitors. Protein concentrations were determined by BCA assay (Pierce). Equal amounts of protein (20–30 µg) were separated by SDS-PAGE and transferred to PVDF membranes (Millipore). Membranes were blocked with 5% non-fat milk in TBS-T for 1 h at room temperature and incubated overnight at 4 °C with primary antibodies against Bax (Cell Signaling Technology, RRID: AB_10557411), Bcl-2 (Cell Signaling Technology, RRID: AB_10694675), phosphorylated ERK (p-ERK; Cell Signaling Technology, RRID: AB_2315112), total ERK (Cell Signaling Technology, RRID: AB_390779), and β-actin (Cell Signaling Technology, RRID: AB_330288) as a loading control. Following washes, membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Bands were visualized using enhanced chemiluminescence (ECL; Thermo Fisher Scientific) and imaged with a gel documentation system. Densitometric analysis was performed using ImageJ software, and protein expression levels were normalized to β-actin. Relative ratios of Bax/Bcl-2 and p-ERK/ERK were calculated to assess modulation of apoptosis and survival signaling pathways. Data and statistical analysis All quantitative data are presented as the mean ± standard deviation (SD). Statistical analyses were performed using GraphPad Prism software (GraphPad Software, San Diego, CA, USA). Comparisons between multiple groups (control, 5 µM, and 10 µM clopidogrel bisulfate) were conducted using one-way analysis of variance (ANOVA), followed by Dunnett’s post-hoc test to compare each treatment group with the control. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Author contributions SJ performed the experiments and analyzed the data. ML wrote the paper and analyzed the data. MK provided advice on the study design, critically discussed the results, and coedited the paper. All authors have read and approved the manuscript. Funding This work was supported by Samjinpharm, Seoul, Republic of Korea (grant number: SJ-IIT-99-01). This work was also supported by 0320240410 from Seoul National University Hospital Research Fund. Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Conflict of interest The authors declare no conflicts of interest. Ethics declarations This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board (IRB) of Seoul National University Hospital (Approval No. H-2101-194-1194). Written informed consent was obtained from all individual participants included in the study. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Mijung Lee, Email: dlalwjd0713@snu.ac.kr. Manho Kim, Email: kimmanho@snu.ac.kr. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.